Schmit, Stephanie L.
Tsai, Ya-Yu
Bonner, Joseph D.
Sanz-Pamplona, Rebeca
Joshi, Amit D.
Ugai, Tomotaka
Lindsey, Sidney S.
Melas, Marilena
McDonnell, Kevin J.
Idos, Gregory E.
Walker, Christopher P.
Qu, Chenxu
Kast, W. Martin
Da Silva, Diane M.
Glickman, Jonathan N.
Chan, Andrew T.
Giannakis, Marios
Nowak, Jonathan A.
Rennert, Hedy S.
Robins, Harlan S.
Ogino, Shuji
Greenson, Joel K.
Moreno, Victor
Rennert, Gad
Gruber, Stephen B.
Funding for this research was provided by:
National Cancer Institute (R01 CA197350, R01 CA197350, P01 CA055075, R01 CA197350, R01 CA197350, R01 CA197350)
Mishima Kaiun Memorial Foundation
Japan Society for the Promotion of Science, and Prevent Cancer Foundation
National Cancer Center (R35 CA197735)
National Cancer Coalition (U01 CA167552)
the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government (2017SGR723)
the Instituto de Salud Carlos III, co-funded by FEDER funds–a way to build Europe (PI17-00092)
the Spanish Association Against Cancer (AECC) Scientific Foundation (GCTRA18022MORE)
Article History
Received: 1 May 2023
Accepted: 9 April 2024
First Online: 25 April 2024
Declarations
:
: All procedures performed were in accordance with the ethical standards of studies involving human participants. Written informed consent was obtained from patients. The MECC study protocol was approved by the City of Hope Institutional Review Board (Protocol Number 19404). The Bellvitge University Hospital Ethics Committee approved the study protocol (PR112/15) for CLX and CRCGEN. The NHS and HPFS studies were conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Harvard T.H. Chan School of Public Health and Brigham and Women’s Hospital (2001P001945) on 20 October 2020.
: Not required.
: GEI: receives/received research funding from Myriad Genetics and Laboratories. JNG: Consultant, Takeda. Consultant, PathAI. None of these activities is relevant to the work presented here or presents a COI. ATC: Consultant Bayer Pharma AG, Boehringer Ingelheim, Pfizer Inc. and grant from Pfizer Inc, for work unrelated to this manuscript. MG: receives/received research funding from Bristol-Myers Squibb, Merck, Servier and Janssen. JAN: receives/received research funding from Illumina, NanoString, and Akoya Biosciences. HSR: Employment, equity, ownership, patents and royalties with Adaptive Biotechnologies. JKG: consultant for Guardant Health. VM: owns stock in Aniling. SBG: Co-founder of Brogent International LLC with equity. All other authors declared that they have no competing interest.